Sarah Cannon Cancer Network Terms & Privacy Policy Tracker

Sarah Cannon Cancer Network

sarahcannon.com

Sarah Cannon Research Institute (SCRI) is one of the world's leading oncology research organizations specializing in community-based clinical trials and drug development. Headquartered in Nashville, Tennessee, and founded in 1993, the institute focuses on providing patients with early access to innovative cancer therapies through a vast network of over 1,300 physicians at more than 250 locations across the United States and United Kingdom. SCRI operates as a comprehensive clinical research organization (CRO) that manages the full lifecycle of clinical development, from first-in-human Phase 1 trials to regulatory approval, and has contributed to the research of the majority of cancer therapies approved by the FDA over the last decade. Its business model integrates advanced site management, precision medicine platforms like Genospace, and strategic collaborations with global biopharmaceutical companies to accelerate trial execution and improve health equity in oncology care.